english Archives - 29 중 3 번째 페이지

Hanmi’s Obesity Drug Shows Up to 30% Weight Loss

Hanmi Pharmaceutical is building a comprehensive, full-cycle treatment portfolio that covers weight loss, management, and prevention through its innovative obesity drug development initiative, the H.O.P (Hanmi Obesity Pipeline) project. [Photo=Hanmi…

Cheon Okhyeon

2025-10-27

HK inno.N Q3 Earnings to Shine on ‘K-CAB Effect’

K-CAB. [사진=HK이노엔] Sales and operating profit projected to rise 19% and 32% year-on-year, respectivelyHK inno.N is expected to post strong results for the third quarter, driven by the robust domestic…

Cheon Okhyeon

2025-10-13

Embracing Autism Through Art: BTS’s Suga Donates $3.6 Million to Open ‘Min Yoon-gi Therapy Center’

The “Min Yoon-gi Therapy Center” at Severance Hospital in Seoul officially opened on Monday, funded by a ₩5 billion ($3.6 million) donation from BTS member Suga (whose real name is…

2426w

2025-09-30

Alteogen Set to Accelerate Licensing After FDA Clears Keytruda SC

The U.S. Food and Drug Administration (FDA) has approved Merck’s (MSD) subcutaneous (SC) formulation of its blockbuster immunotherapy Keytruda, developed using Alteogen’s proprietary technology. Following the decision, analysts forecast not…

Cheon Okhyeon

2025-09-22

AbClon’s Nespe-cel CAR-T Therapy Gains Orphan Drug Status in Korea

AbClon, a Korean antibody drug developer, announced on September 18 that its next-generation CAR-T (chimeric antigen receptor T-cell) therapy Nespe-cel (AT101) has been designated as a developmental-stage orphan drug by…

Cheon Okhyeon

2025-09-18

SK Biopharm’s Cenobamate Shows Efficacy in Global Phase 3 Generalized Seizure Trial

SK Biopharm announced that its innovative epilepsy drug cenobamate has shown efficacy in patients with generalized seizures in a Phase 3 clinical trial, marking a key step toward expanding its…

Cheon Okhyeon

2025-09-16

HK inno.N “K-CAB Reduces Risk of Gastrointestinal Bleeding in Heart Attack Patients”

HK inno.N announced on the 10th that a recent comparative analysis has confirmed the safety and efficacy of its gastroesophageal reflux disease (GERD) drug 'K-CAB (tegoprazan)' against conventional proton pump…

Cheon Okhyeon

2025-09-10

KOREA UNITED PHARM Set to Surpass KRW 300 Billion in Sales This Year

KOREA UNITED PHARM, INC. is on track to exceed KRW 300 billion (USD 217 million) in annual sales for the first time in its history, backed by a steady stream…

Cheon Okhyeon

2025-09-01

GC Biopharma Files Phase 3 Trial for Two-Dose Chickenpox Vaccine in Thailand

GC Biopharma announced on the 27th that it has submitted an Investigational New Drug (IND) application to Thailand’s Food and Drug Administration for a Phase 3 clinical trial of its…

Cheon Okhyeon

2025-08-27

Fierce ADC Battlefield… Celltrion’s Bet Is on ‘biobetter’

Celltrion, which has entered the rapidly emerging field of antibody–drug conjugates (ADCs), is seeking to differentiate itself with a “biobetter ADC” that improves or overcomes the shortcomings of existing antibody…

Cheon Okhyeon

2025-08-25